Cutler Group LP Aldeyra Therapeutics, Inc. Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$2.43 - $4.85 $6,954 - $13,880	-2,862 Reduced 64.2%	1,596 $6,000
Q4 2021 Jan 18, 2022	SELL	$3.5 - $9.63 $25,280 - $69,557	-7,223 Reduced 61.84%	4,458 $17,000
Q3 2021 Oct 26, 2021	BUY	$7.94 - $11.31 $92,596 - $131,897	11,662 Added 61378.95%	11,681 $102,000
Q4 2018 Feb 05, 2019	SELL	$7.26 - $13.29 $19,979 - $36,574	-2,752 Reduced 99.31%	19 $0
Q3 2018 Nov 07, 2018	BUY	$6.8 - $14.35 $14,082 - $29,718	2,071 Added 295.86%	2,771 $38,000
Q2 2018 Aug 10, 2018	BUY	$6.95 - $9.18 $4,865 - $6,426	700 New	700 $5,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $283M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.